PERTH, Australia – Novartis AG's recent tender offer to acquire radiopharmaceuticals specialist Advanced Accelerator Applications SA (AAA) for $3.9 billion could bode well for Aussie radiopharma company Telix Pharmaceuticals Ltd., which announced its IPO to raise A$50 million (US$38.4 million) on the Australian Securities Exchange.
ADELAIDE, Australia – Australia's life sciences sector is expected to bring in almost A$3 trillion (US$2.2 trillion) by 2025. The government is pumping funds into the sector and working with industry to update regulations and building needed translational infrastructure to attract global attention.
ADELAIDE, Australia – Australia's life sciences sector is expected to bring in almost A$3 trillion (US$2.2 trillion) by 2025. The government is pumping funds into the sector and working with industry to update regulations and building needed translational infrastructure to attract global attention.
PERTH, Australia – After a few tumultuous years for Melbourne-based Phosphagenics Ltd., the company is recreating itself with a capital raising in the works and a new spate of global deals. CEO Ross Murdoch told BioWorld that he joined Phosphagenics in 2015 to help rebuild the firm's reputation after former CEO Esra Ogru swindled millions from the company.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) received mixed comments from industry on two related draft guidances for reporting adverse events for biologics and for adopting an EU guideline on good pharmacovigilance practices.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) received mixed comments from industry on two related draft guidances for reporting adverse events for biologics and for adopting an EU guideline on good pharmacovigilance practices.
PERTH, Australia – Australian biotech Propanc Biopharma Inc. is advancing its lead product, PRP, toward the clinic in ovarian and pancreatic cancers. The Melbourne-based company reported that recent studies show that the once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen reduced epithelial to mesenchymal transition (EMT) markers, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells.
PERTH, Australia – Australian biotech Propanc Biopharma Inc. is advancing its lead product, PRP, toward the clinic in ovarian and pancreatic cancers. The Melbourne-based company reported that recent studies show that the once-daily intravenous combo of pancreatic proenzymes trypsinogen and chymotrypsinogen reduced epithelial to mesenchymal transition (EMT) markers, which not only reverses the EMT process, thereby stopping tumor progression and metastasis, but also represses the development of cancer stem cells.
